Sarah Tanksley ráðin framkvæmdastjóri gæðaeftirlits hjá Alvotech
October 11, 2022 17:00 ET
|
Alvotech
Alvotech (NASDAQ First North:ALVO) tilkynnti í dag að Sarah Tanksley hafi verið ráðin framkvæmdastjóri gæðaeftirlits hjá Alvotech en hún tekur við af Reem Malki, sem beðist hefur lausnar af...
Alvotech Appoints Sarah Tanksley as Chief Quality Officer
October 11, 2022 17:00 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Sarah Tanksley will join its...
Alvotech og STADA hefja sölu á Hukyndra í Sviss og auka aðgengi sjúklinga að adalimumab
September 22, 2022 08:00 ET
|
Alvotech
Alvotech (NASDAQ First North: ALVO) og STADA Arzneimittel AG (STADA) tilkynntu í dag að sala og markaðssetning væri hafin í Sviss á Hukyndra, líftæknihliðstæðulyfi við Humira (adalimumab), sem...
Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®
September 22, 2022 08:00 ET
|
Alvotech
Hukyndra® increases availability of high-concentration, low-volume, citrate-free presentations of adalimumabExclusive partnership between Alvotech and STADA in Europe includes Hukyndra® and six...
Alvotech kynnir uppgjör fyrir fyrstu sex mánuði ársins 2022 og skýrir frá helstu áföngum frá áramótum
August 31, 2022 17:00 ET
|
Alvotech
Tryggð fjármögnun að andvirði 185 milljóna Bandaríkjadala með samruna við sérhæfða yfirtökufélagið OACB og nýju hlutafé frá innlendum og erlendum fjárfestumHlutabréf félagsins tekin til...
Alvotech Reports First Half 2022 Financial Results and Business Update
August 31, 2022 17:00 ET
|
Alvotech
Secured funding of approximately $185 million in gross proceeds through the merger with OACB (the “Business Combination”) and private placement investment in public equity (PIPE) financingDebuted as...